Teva Loses Generic Actonel Case, But Wins Protonix Lawsuit

Teva Pharmaceuticals USA has lost its latest bid to invalidate a patent covering Procter & Gamble’s (P&G) osteoporosis drug Actonel. The U.S. Court of Appeals for the Federal Circuit affirmed a decision upholding the validity of P&G’s ’122 patent that claims the compound risedronate, Actonel’s (risedronate sodium) active ingredient. As a result of the decision, Teva expects to market its generic Actonel tablets no later than June 2014, when exclusivity on the ’122 patent expires. Separately, Teva was one of three drugmakers to win in the same court against Altana and Wyeth in an ongoing consolidated case involving the heartburn drug Protonix (pantoprazole sodium).
Generic Line